A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
What is the purpose of this trial?
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders or cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
- Trial withNational Cancer Institute (NCI)
- Start Date11/07/2019
- End Date08/30/2022
- Last Updated08/13/2020
- Study HIC#2000025640